Diana E. Ramirez-Ardila

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen

John A. Foekens, Stefan Sleijfer, M. Weerts, 2016, Oncotarget.

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

S. Sleijfer, J. Foekens, M. Look, 2013, Breast Cancer Research and Treatment.

Decreased expression of ABAT and STC2 hallmarks ER‐positive inflammatory breast cancer and endocrine therapy resistance in advanced disease

F. Bertucci, J. Foekens, A. Sieuwerts, 2015, Molecular oncology.

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis

E. Berns, Jean C. A. Helmijr, J. Martens, 2017, Translational oncology.